1. Core Statutory Framework and Consumer Protections
The FDCA, enacted in 1938 and amended multiple times, creates a baseline of safety and transparency obligations that apply to nearly all drugs and cosmetics entering interstate commerce. The statute distinguishes between drugs and cosmetics based on intended use and claims made by the manufacturer, not the product's physical form. A product claiming to treat, cure, mitigate, or prevent disease is regulated as a drug; a product intended solely to cleanse, beautify, or alter appearance is regulated as a cosmetic. This distinction matters because drugs face far stricter pre-market approval requirements, while cosmetics generally do not require FDA approval before sale, though they remain subject to safety and labeling rules.
Under the FDCA, manufacturers must ensure products are safe for their intended use, contain only approved ingredients (for drugs), and bear accurate labeling that discloses active ingredients, warnings, and usage instructions. False or misleading advertising that overstates benefits, conceals material risks, or makes unsubstantiated health claims violates the statute. Consumers harmed by adulterated, misbranded, or unsafe products may pursue remedies through the FDA's enforcement mechanisms, state attorneys general, or private litigation under various consumer protection statutes and common law theories.
Fda Oversight and Regulatory Authority
The Food and Drug Administration enforces the FDCA through inspection, testing, warning letters, administrative orders, product seizures, and criminal prosecution. The FDA maintains jurisdiction over manufacturing facilities, ingredient sourcing, labeling accuracy, and post-market surveillance. When the FDA identifies a safety hazard, it may issue a recall or import alert and work with manufacturers to remove dangerous products from distribution. Consumers can report adverse events to the FDA's MedWatch system for drugs or through the Safety Reporting Portal for cosmetics, creating a record that may trigger agency investigation and enforcement action.
New York State Consumer Protection Provisions
In New York, the General Business Law Section 349 prohibits deceptive or unfair practices in consumer transactions, including the sale of drugs and cosmetics with false or misleading advertising. New York courts have consistently held that a product's failure to comply with FDCA standards or FDA labeling requirements constitutes prima facie evidence of deception under state law. This means a consumer or the New York Attorney General can bring an action in Supreme Court alleging that a drug or cosmetic product violated federal safety or labeling standards, and the violation itself supports a claim for damages or injunctive relief without requiring proof of intent to deceive. The practical significance is that consumers can leverage federal regulatory violations as the foundation for state-law remedies, including restitution and civil penalties.
2. What Makes a Drug or Cosmetic Misbranded or Adulterated
A drug is misbranded if its label fails to include required information, bears false or misleading statements, or omits material warnings. A cosmetic is misbranded if it is falsely labeled as to identity, quality, or origin, or if claims made on the label or in advertising exceed what the product can safely deliver. A product becomes adulterated if it contains unapproved color additives, non-food-grade ingredients, bacterial or chemical contaminants, or substances that render it unsafe for its intended use. Adulteration can occur during manufacturing, storage, or distribution if proper controls are not maintained.
Common violations include:
- Cosmetics marketed as hypoallergenic or dermatologist-tested without substantiation or standardized meaning
- Skincare products claiming to treat acne, wrinkles, or skin conditions without FDA approval as drugs
- Dietary supplements or topical products making disease-prevention claims not permitted under their regulatory category
- Failure to disclose allergens, heavy metals, or undisclosed active ingredients
- Products manufactured in facilities with inadequate sanitation or contamination controls
When a consumer suffers injury from a misbranded or adulterated product, the violation creates liability for the manufacturer, distributor, or retailer. In New York, consumers may pursue class actions and consumer defense claims; our firm's experience with class actions and consumer defense matters shows that coordinated claims often uncover systemic labeling failures or ingredient sourcing problems affecting thousands of purchasers. A single injured consumer can also bring an individual action for breach of warranty, negligence, or strict liability, seeking medical expenses, pain and suffering, and restitution of the purchase price.
3. Harm and Liability Pathways for Consumers
A consumer injured by a drug or cosmetic product has multiple avenues to pursue accountability. The first step is documenting the injury, the product used, and the date of purchase or use. Medical records, photographs, receipts, and any communications with the manufacturer or retailer strengthen a claim. Once injury is documented, consumers can report the incident to the FDA and file a complaint with the New York Attorney General, either of which may trigger investigation and enforcement action against the manufacturer.
Private Litigation and Damages
A consumer can file a civil lawsuit against the manufacturer, distributor, or retailer in New York state or federal court. Claims typically allege breach of express or implied warranty, failure to warn, negligent manufacturing, strict liability for defective products, or violation of consumer protection statutes. Damages may include the cost of medical treatment, lost wages, pain and suffering, and punitive damages if the defendant's conduct was reckless or grossly negligent. In cases involving widespread harm, a consumer may participate in a class action, which consolidates claims and allows the class to pursue injunctive relief (such as mandatory recalls or corrective advertising), and monetary recovery on behalf of all affected purchasers.
Class Action and Consumer Defense Mechanisms
Class actions are particularly effective when a cosmetic or drug product causes systemic harm across many consumers due to a design defect, manufacturing failure, or deceptive labeling. Our firm regularly represents consumer classes in product liability litigation, and we have seen how coordinated discovery uncovers internal communications revealing that manufacturers knew of safety risks but failed to disclose them or continued selling despite complaints. Class actions and consumer defense strategies allow individual consumers to pool resources, share litigation costs, and hold large manufacturers accountable for conduct that might otherwise go unchallenged. Settlement or judgment in a class action can result in monetary awards to class members, product recalls, reformulation requirements, and corrective advertising that informs other consumers of the risks.
4. Design, Labeling, and Manufacturing Defects
A drug or cosmetic product can be defective in three ways: design, manufacturing, or labeling. A design defect exists when the product's inherent composition or formulation creates an unreasonable risk of harm that could have been reduced by an alternative design. A manufacturing defect occurs when the product deviates from its intended design during production, such as contamination or improper ingredient ratios. A labeling defect arises when warnings, instructions, or ingredient disclosures are absent, inadequate, or misleading.
In New York litigation, courts recognize that a product's failure to comply with FDCA standards or FDA guidance often constitutes evidence of a labeling or design defect. For example, if a sunscreen fails to provide the SPF protection claimed on its label, or if a cosmetic contains an unapproved color additive, the regulatory violation supports the consumer's claim that the product was defective and unsafe. The burden shifts to the manufacturer to demonstrate that the product was safe despite the violation.
20 May, 2026
